FDA granted IND clearance for IDEAYA’s Phase 1/2 MTAP-deletion trials in solid tumors

CAR-T Digest - August 2020

May 22, 2023: IDE397 / AMG 193 / Solid tumors / Ideaya Biosciences: IND approved for Phase 1/2 study

The FDA cleared an IND for Phase 1/2 trial in MTAP-deletion solid tumors evaluating the combination of IDE397 (MAT2A) and AMG 193 (PRMT5)
IDE397 is currently being evaluated as a monotherapy in solid tumors, NSCLC, esophagogastric, and bladder cancer
Phase 1/2 trial of IDE397 in combination with AMG 193 is being conducted in collaboration with Amgen
“We are pleased to collaborate with Amgen to clinically evaluate the IDE397 and AMG 193 combination as a potential first-in-class treatment for patients having solid tumors with MTAP deletion. We believe that evaluation of this combination represents an exciting and highly rational clinical study for patients with MTAP-deletion tumors, based on the observed preclinical efficacy, tolerability, and selectivity,” said Dr. Darrin M. Beaupre, M.D., Ph.D., Chief Medical Officer, IDEAYA Biosciences